RxDoctor Payments Data

Todd Campbell, MD

Urology · Roseville, MINPI 1184680662

Payments from drug & device makers

$11,263in general payments, 2019–2025

Across 356 payments — averaging $31.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Coloplast$1K
  • Olympus Corporation Of The Americas$840
  • Astellas Pharma US Inc$728
  • Boston Scientific$725
  • Rochester Medical Corporation$691
  • plus $6K from 46 others

What the payments were for

  • Travel & lodging$7056%
  • Food & beverage$10,35192%
  • Education$2072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,263 in reported general payments places this provider in the 75th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$193,399
Medicare patients
499
Services billed
3,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide59$832,353
MyrbetriqMirabegron145$108,055
GemtesaVibegron40$46,715
Mirabegron ErMirabegron28$19,264
Tamsulosin Hcl772$16,445
Oxybutynin Chloride ErOxybutynin Chloride363$11,514
Trospium Chloride ErTrospium Chloride54$9,953
Solifenacin Succinate159$5,636
Methenamine Hippurate41$4,954
Alfuzosin Hcl ErAlfuzosin Hcl158$4,831
Bicalutamide48$4,291
Trimethoprim65$3,859
Tolterodine Tartrate ErTolterodine Tartrate25$3,847
Bethanechol Chloride24$3,229
NitrofurantoinNitrofurantoin Macrocrystal56$2,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$728$940,408204 claims
Sumitomo Pharma America, Inc.Gemtesa$209$46,71540 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 400 urology providers in Michigan.

Other urology in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →